With negative FDA panel vote, AstraZeneca may review Lynparza’s narrow sign in prostate cancer – FiercePharma

  1. With FDA panel’s negative vote, AstraZeneca may examine Lynparza’s narrow sign in prostate cancerFiercePharma
  2. US FDA panel backs restricted use of AstraZeneca’s prostate cancer drugReuters.com
  3. FDA panel rejects broad indication of olaparib in metastatic CRPCToday
  4. FDA panel votes that proposed indication for olaparib/abiraterone should be limited to BRCA mutant mCRPCOncLive
  5. FDA casts doubt on Merck/AstraZeneca cancer drug for prostate cancer ahead of Adcomm meetingYahoo finance
  6. See full coverage on Google News

Leave a Comment

Your email address will not be published. Required fields are marked *